https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53995 Wed 28 Feb 2024 15:22:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50302 Wed 28 Feb 2024 15:06:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47500 Wed 24 Jan 2024 14:49:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32668 Wed 19 Jan 2022 15:16:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36948 Wed 19 Jan 2022 15:16:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48016 To the Editor: The major 17q12-21 asthma susceptibility and exacerbation locus1 has been identified as the only genetic locus that is also reproducibly associated with total white blood cell count.2 However, it is not known whether there is a common gene within this locus that links these phenotypic traits. The colony-stimulating factor-3 (CSF3) gene, alternatively known as G-CSF, resides within this locus. CSF3 binds exclusively to CSF3 receptor (CSF3R, or CD114/G-CSFR), which is highly expressed on mature neutrophils and to a lesser extent on mononuclear cells, platelets, and lung interstitial stromal cells. Although CSF3R/CD114 signaling can dictate the intensity of the host defense inflammatory response during bacterial infection by regulating neutrophil granulopoiesis and trafficking, its role in the infection-dependent transition to persistent, severe asthma has not been investigated. Neonatal colonization of the nasopharynx by potentially pathogenic bacteria including Streptococcus pneumoniae is also a risk factor for asthma development.3 The Childhood Asthma Study found that children with atopy and chronic wheeze at age 5 years were twice as likely to have been colonized with S pneumoniae as neonates.4 The authors suggest that transient incursions of nasopharyngeal bacteria into the lower airways triggered by a fever-causing viral respiratory infection (respiratory syncytial virus or influenza virus) increases the risk of developing persistent asthma in atopic children. However, a plausible mechanism linking these cofactors is yet to be identified. In this study, we tested the hypothesis that CSF3-CSF3R signaling dictates the severity of infectiondependent asthma at a cellular and molecular level.]]> Wed 15 Feb 2023 10:19:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47108 Wed 14 Dec 2022 10:05:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18377 Wed 11 Apr 2018 15:30:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22606 16 years) were admitted with confirmed influenza to one of 15 of 17 FluCAN sentinel hospitals (excluding 2 paediatric hospitals). Of these, 47% were over 65 years of age, 10% were Indigenous Australians, 3.3% were pregnant and 85% had chronic co-morbidities. The majority of cases were due to influenza A. Influenza B was detected in 7% of patients. There were a large number of hospital admissions detected with confirmed influenza in this national observational surveillance system in 2014. These are estimated to represent a national annual burden of around 15,000 admissions and almost 100,000 bed-days nationally.]]> Wed 11 Apr 2018 10:29:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33415 Wed 10 Nov 2021 15:04:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50856 Wed 09 Aug 2023 10:06:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55876 Wed 03 Jul 2024 14:09:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41826 Tue 28 Mar 2023 11:27:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46348 Tue 15 Nov 2022 14:13:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54220 65 years of age, 36 (8%) were children (< 16 years), 6 (1%) were Aboriginal and Torres Strait Islander peoples, 4 (1%) were pregnant and 289 (65%) had chronic comorbidities. COVID-19 hospital admissions peaked between weeks 13 and 15 (first wave) nationally, and again between weeks 31 and 35 (Victoria), with most admissions represented by those above 40 years of age. Discussion: There was an unusually low number of hospital admissions with laboratory-confirmed influenza in this season, compared to recent seasons. This is likely to be due to effective public health interventions and international border closures as a result of a rise in COVID-19 respiratory infections and associated hospitalisations.]]> Tue 13 Feb 2024 12:02:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39066 in vitro release study, molecular simulations and was evaluated for in vitro anti-inflammatory activity. Results: Results showed that Nio-Curc had a mean particle size of 284.93 ± 14.27 nm, zeta potential of -46.93 and encapsulation efficacy of 99.62%, which demonstrates optimized physicochemical characteristics. Curcumin release in vitro could be sustained for up to 24 h. Additionally, Nio-Curc effectively reduced mRNA transcript expression of pro-inflammatory markers; IL-6, IL-8, IL-1β and TNF-a in immortalized human airway basal cell line (BCi-NS1.1). Conclusion: In this study, we have demonstrated that Nio-Curc mitigated the mRNA expression of pro-inflammatory markers in an in vitro study, which could be applied to treatment of asthma with further studies.]]> Tue 03 May 2022 12:13:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54560 Thu 29 Feb 2024 10:27:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52111 Thu 28 Sep 2023 14:57:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41166 Thu 28 Jul 2022 09:55:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45652 Thu 23 Mar 2023 13:58:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33591 Thu 22 Nov 2018 13:41:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38736 Thu 20 Jan 2022 16:12:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54275 Thu 15 Feb 2024 14:39:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39904 Thu 14 Jul 2022 11:58:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52205 Thu 05 Oct 2023 10:15:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55045 6 years). Separate paediatric and adult diagnostic management algorithms should be followed. Management of the underlying condition(s) should follow specific disease guidelines, as well as address adverse environmental exposures and patient/carer concerns. First Nations adults and children should be considered a high risk group. The full statement from the Thoracic Society of Australia and New Zealand and Lung Foundation Australia for managing chronic cough is available at https://lungfoundation.com.au/resources/cicada-full-position-statement. Changes in management as a result of this statement: ; Algorithms for assessment and diagnosis of adult and paediatric chronic cough are recommended. ; High quality evidence supports the use of child-specific chronic cough management algorithms to improve clinical outcomes, but none exist in adults. ; Red flags that indicate serious underlying conditions requiring investigation or referral should be identified. ; Early and effective treatment of chronic wet/productive cough in children is critical. ; Culturally specific strategies for facilitating the management of chronic cough in First Nations populations should be adopted. ; If the chronic cough does not resolve or is unexplained, the patient should be referred to a respiratory specialist or cough clinic.]]> Thu 04 Apr 2024 13:51:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39264 Thu 02 Jun 2022 11:03:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8459 Sat 24 Mar 2018 08:38:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7886 Sat 24 Mar 2018 08:35:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10647 Sat 24 Mar 2018 08:13:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18281 Sat 24 Mar 2018 08:04:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19226 Sat 24 Mar 2018 07:54:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5105 Sat 24 Mar 2018 07:48:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5682 Sat 24 Mar 2018 07:47:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23340 Sat 24 Mar 2018 07:13:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36574 Mon 24 Jul 2023 18:02:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49260 Mon 08 May 2023 11:03:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42611 Fri 26 Aug 2022 14:51:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42171 Fri 26 Aug 2022 08:02:59 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55396 Fri 24 May 2024 10:54:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:56266 Fri 23 Aug 2024 09:51:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40051 40%. There is limited safety or efficacy data in patients with ppFEV1 < 40%. We determined whether LUM/IVA in patients with ppFEV1 < 40 would reduce the rate of pul- monary exacerbations. Methods: This was a case control study performed on patients > 12 years, homozygous for Phe508del CFTR mutation and with ppFEV1 < 40%. Control subjects were matched for age, sex and ppFEV1, and had mutations ineligible for LUM/IVA. We assessed the rate of pulmonary exacerbations requiring intravenous antibiotics, the mean rate of change in ppFEV1 over 12 months and all adverse events. Results: Data was collected from 7 Australian CF centres on 105 patients; 72 on LUM/IVA and 33 controls. LUM/IVA demonstrated a large reduction in exacerbations with an incident rate ratio of 0.455 (95%CI; 0.306 –0.676), p < 0.001 after adjusting for the number of exacerbations in the previous 12 months. LUM/IVA prolonged the time to first exacerbation and reduced the rate of decline in ppFEV1 over 12 months. Adverse events were common; chest tightness or dyspnoea was experienced by 55% and resulted in cessation of treatment in 32%. Conclusions: Treatment with LUM/IVA resulted in a substantially lower rate of pulmonary exacerbations, prolonged time to first exacerbation and slowed the rate of decline of ppFEV1 in participants with severe lung disease. Adverse reactions to LUM/IVA however were unacceptably frequent, and resulted in a very high discontinuation rate.]]> Fri 22 Jul 2022 13:27:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39682 Fri 17 Jun 2022 15:46:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51754 Fri 15 Sep 2023 18:27:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41789 Fri 12 Aug 2022 12:17:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46080 Fri 11 Nov 2022 10:10:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32830 Fri 03 Dec 2021 10:34:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42789 Fri 02 Sep 2022 14:04:09 AEST ]]>